Vibegron, a Novel Potent and Selective β3-Adrenoreceptor Agonist, for the Treatment of Patients with Overactive Bladder: A Randomized, Double-blind, Placebo-controlled Phase 3 Study

Trial registration ​JapicCTI-152936. http://www.clinicaltrials.jp/user/cteDetail.jsp.